Dementia Care Research and Psychosocial Factors

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Disease-modifying therapies, including anti-amyloid monoclonal antibodies, offer new treatment avenues for early Alzheimer's Disease (AD).
• Effective implementation in community clinics necessitates careful patient selection, timely access, and adverse event monitoring.
• Key Performance Indicators (KPIs) are essential for optimizing the delivery and outcomes of these novel AD treatments in real-world settings.

Purpose of the Study:

• To develop and evaluate a clinical program for diagnosing and treating early AD within community neurology clinics.
• To assess the feasibility and safety of administering anti-amyloid monoclonal antibody therapy in community settings.
• To identify and analyze Key Performance Indicators (KPIs) for guiding clinical practice and standardizing care.

Main Methods:

• A clinical program was established in Southern California for early AD diagnosis and treatment.
• Patients with confirmed early AD received anti-amyloid monoclonal antibody therapy via in-clinic or external infusion centers.
• Key Performance Indicators (KPIs) were identified, and demographic/clinical data were analyzed using non-parametric statistics and regression analyses.

Main Results:

• A total of 506 patients were enrolled; 108 received treatment, 140 were pending, and 258 were disqualified.
• Key metrics included Negative AD Biomarker Rate, Treatment Rate, Door-to-Treatment Time, Dropout Rate, and Amyloid-Related Imaging Abnormalities (ARIA) rates.
• Evaluation and treatment of early AD with anti-amyloid therapy were found to be feasible and safe in community neurology clinics.

Conclusions:

• Streamlined triaging, simplified care coordination, and rigorous quality/safety monitoring are critical for successful AD treatment programs.
• Monitoring specific KPIs (Negative AD Biomarker Rate, Treatment Rate, Door-to-Treatment time, Dropout Rate, ARIA rates) aids in standardizing and scaling care.
• These KPIs provide a structured framework for optimizing treatment outcomes and expanding access to disease-modifying therapies for Alzheimer's Disease.